INT161382

Context Info Confidence 0.61 First Reported 2006 Last Reported 2011 Negated 1 Speculated 0 Reported most in Body Documents 25 Total Number 26 Disease Relevance 12.97 Pain Relevance 2.13

Golgi apparatus (KRT20) cytoplasm (KRT20)

Anatomy Link Frequency muscle 1 brain 1 bone marrow 1 corneal endothelial cells 1 plasmablasts 1 KRT20 (Homo sapiens)

Pain Link Frequency Relevance Heat Kinase C 7 100.00 cytokine 23 99.96 metalloproteinase 1 97.68 rheumatoid arthritis 319 97.48 abdominal pain 3 92.52 Inflammation 42 88.08 imagery 10 84.68 Arthritis 64 81.64 methotrexate 34 78.08 corticosteroid 16 76.72

Disease Link Frequency Relevance Heat Cancer 145 100.00 Disease 363 99.88 Apoptosis 33 98.48 Bacterial Infection 34 98.36 Lymphatic System Cancer 95 97.82 Rheumatoid Arthritis 347 97.48 Infection 136 96.96 Repression 11 94.92 Thyroid Nodule 2 94.72 Hodgkin's Disease 11 94.12

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

It is generally accepted that the CD20 protein functions as a channel regulator of ion influx (Ernst et al 2005) and that this membrane-bound protein is specifically found on the membrane of B-cells but is not expressed on stem cells nor on terminally-differentiated plasma cells.

Localization (found) of CD20 in stem cells

1) Confidence 0.61 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721296 Disease Relevance 0.87 Pain Relevance 0.28

Still, not all CD19+ B-cells were eliminated in bone marrow as pre-B-cells and CD20?

Localization (eliminated) of CD20 in bone marrow

2) Confidence 0.61 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721296 Disease Relevance 0.37 Pain Relevance 0.15

Furthermore, residual RTX remains in patients’ serum for three to six months after treatment and could potentially block CD20 binding sites.46 Preclinical studies using human lymphoma cell lines, patient-derived specimens, and mouse xenograft models have shown that prior RTX therapy reduces CD20 binding, tumor-specific localization, and tumor control for 131I-TST.46 Despite this preclinical data, 131I-TST has been shown to be clinically effective in RTX-refractory relapsed low grade B-cell NHL as discussed previously.31 Future clinical studies should help determine whether inclusion of RTX in induction chemotherapy regimens abrogates the incremental therapeutic gain of consolidation 131I-TST found in the studies listed in Table 4.

Localization (localization) of CD20 in B-cell associated with lymphatic system cancer and cancer

3) Confidence 0.24 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.82 Pain Relevance 0

In the group of patients suspected of CTD, the frequency of CD27++/CD20?

Localization (frequency) of CD20 associated with disease

4) Confidence 0.23 Published 2007 Journal J Clin Immunol Section Body Doc Link PMC2039801 Disease Relevance 0.51 Pain Relevance 0

In the healthy control group, the mean frequency of CD27++/CD20?

Localization (frequency) of CD20

5) Confidence 0.23 Published 2007 Journal J Clin Immunol Section Body Doc Link PMC2039801 Disease Relevance 0.68 Pain Relevance 0

Whether complete depletion of peripheral B-cells and remaining CD20- plasmablasts may be used as a biomarker of clinical response needs further careful analysis in RA.

Localization (depletion) of CD20 in plasmablasts associated with rheumatoid arthritis

6) Confidence 0.18 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376077 Disease Relevance 1.22 Pain Relevance 0.25

PBMCs and BAL cells were stained with antibodies directed against CD20, IgD and CD27 to distinguish between three subsets: CD27-IgD+ (most likely naïve), CD27+IgD+, and CD27+IgD?

Localization (directed) of CD20

7) Confidence 0.14 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2770849 Disease Relevance 0.80 Pain Relevance 0

The syndecan-1 positive cells did not co-localise with CD20 indicating that they were not immature or mature B cells (fig 2C,D).

Localization (localise) of CD20 in mature B cells

8) Confidence 0.14 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2563418 Disease Relevance 1.17 Pain Relevance 0.40

For co-localisation of syndecan-1 and CD20, sections were treated with anti-syndecan-1 (5 ?

Localization (localisation) of CD20

9) Confidence 0.14 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2563418 Disease Relevance 0 Pain Relevance 0

No co-localisation was observed between CCR9 and CD20 (B lymphocytes) or CD3 (T lymphocytes) respectively in either RA or non-RA synovia (data not shown).

Localization (localisation) of CD20 in T lymphocytes associated with rheumatoid arthritis

10) Confidence 0.11 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2945064 Disease Relevance 0.99 Pain Relevance 0.52

The antibodies used for lineage-specific markers included CD3 (clone SP34-2), CD4 (clone L200), CD8 (clone RPA-T8), CD14 (clone M5E2), CD13 (clone L138), CD20 (clone L27), and CD34 (clone 563).

Localization (clone) of CD20

11) Confidence 0.09 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2765621 Disease Relevance 0 Pain Relevance 0

These studies are often focused on specific protein families, such as G-protein coupled receptors (8), nuclear receptors (9) and kinases (10), but global pharmacology profiles of chemicals are considered as well (1,2).

Localization (receptors) of protein

12) Confidence 0.08 Published 2011 Journal Nucleic Acids Research Section Body Doc Link PMC3013776 Disease Relevance 0.20 Pain Relevance 0.03

These studies are often focused on specific protein families, such as G-protein coupled receptors (8), nuclear receptors (9) and kinases (10), but global pharmacology profiles of chemicals are considered as well (1,2).

Localization (receptors) of protein

13) Confidence 0.08 Published 2011 Journal Nucleic Acids Research Section Body Doc Link PMC3013776 Disease Relevance 0.20 Pain Relevance 0.03

Two-dimensional gel protein separation of extracts from cultured human corneal endothelial cells

Localization (separation) of protein in corneal endothelial cells

14) Confidence 0.04 Published 2008 Journal Molecular Vision Section Body Doc Link PMC2565687 Disease Relevance 0 Pain Relevance 0

Protein sample preparation

Localization (preparation) of Protein

15) Confidence 0.04 Published 2008 Journal Molecular Vision Section Body Doc Link PMC2565687 Disease Relevance 0.48 Pain Relevance 0

Different lymphocyte subsets were quantified on the basis of surface antigen expression (CD3, CD4, CD8, CD20), secreted cytokines (IL-4, IL-6, IFNgamma) and Fas and FasL proteins in the gastric mucosa.

Localization (secreted) of CD20 in lymphocyte associated with cytokine

16) Confidence 0.03 Published 2009 Journal Acta Biochim. Pol. Section Abstract Doc Link 19572057 Disease Relevance 0.57 Pain Relevance 0.19

-Synuclein is a relatively small (112–140 amino acids in length) presynaptic nonsecreting protein and makes up around 1% of the total protein within the brain and less than 0.001% of the CSF proteome [37].

Localization (nonsecreting) of protein in brain

17) Confidence 0.02 Published 2010 Journal International Journal of Alzheimer's Disease Section Body Doc Link PMC2965495 Disease Relevance 0.90 Pain Relevance 0

Recent studies indicate that pp71 stimulates the release of ATRX, a cell protein with chromatin remodelling activity, from ND10 in a very early event after infection, suggesting that ATRX is an important component of the cellular intrinsic defences to HCMV [21].

Localization (release) of protein associated with cytomegalovirus infection and infection

18) Confidence 0.01 Published 2009 Journal Virol J Section Body Doc Link PMC2693105 Disease Relevance 0.91 Pain Relevance 0

This protein is found in the cytoplasm, where it regulates apoptosis [8,9], and also in nuclear structures known as nuclear domain 10 (ND10) [10-12].

Localization (found) of protein associated with apoptosis

19) Confidence 0.01 Published 2009 Journal Virol J Section Body Doc Link PMC2693105 Disease Relevance 0.66 Pain Relevance 0

The samples were positive for anti-BCL-2, CD10, CD20 and CD68 antibodies and negative for CD3 (in the follicles).

Neg (negative) Localization (negative) of CD20 in follicles

20) Confidence 0.01 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2862671 Disease Relevance 0.89 Pain Relevance 0.15

General Comments

This test has worked.